The FDA granted approval for Toviaz, a once-daily drug from UCB and Pfizer designed to treat adults with overactive bladders. The clearance is based on two 12-week trials showing the medicine's efficacy versus placebo in decreasing urinary frequency. Pfizer paid as much as $210 million in April 2006 to secure the U.S. rights to Toviaz from Schwarz Pharma of Germany.

Full Story:
Bloomberg, WebMD

Related Summaries